Skip to main content
Competition Policy

On 28 May 2024, the European Commission approved IPCEI Med4Cure. A total of 13 companies from six Member States (Belgium, France, Hungary, Italy, Slovakia and Spain) are participating in this IPCEI with 14 projects.

This IPCEI will notably contribute to European Health Union’s objectives by delivering innovations addressing diseases for which there are no satisfactory means of prevention or treatment and by increasing the EU’s preparedness for emerging health threats.

The six Member States will provide up to €1 billion in public funding in the coming years, which is expected to unlock an additional €5,9 billion in private investments.